Last reviewed · How we verify
Recombinant human Neuregulin for injection
Recombinant human Neuregulin for injection is a growth factor that promotes cardiac repair and regeneration.
Recombinant human Neuregulin for injection is a growth factor that promotes cardiac repair and regeneration. Used for Acute myocardial infarction, Heart failure.
At a glance
| Generic name | Recombinant human Neuregulin for injection |
|---|---|
| Also known as | Neucardin |
| Sponsor | Zensun Sci. & Tech. Co., Ltd. |
| Drug class | Growth factor |
| Target | ErbB4 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by binding to and activating the ErbB4 receptor on cardiac cells, stimulating the expression of genes involved in cardiac development and function. This leads to improved cardiac function and reduced fibrosis.
Approved indications
- Acute myocardial infarction
- Heart failure
Common side effects
- Injection site reaction
- Flu-like symptoms
- Fatigue
Key clinical trials
- Evaluate the Effect of Injectable Neucardin on the Cardiac Function of Subjects With Chronic Systolic Heart Failure (PHASE3)
- Survival Study of the Recombinant Human Neuregulin-1β in Subjects With Chronic Heart Failure. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: